The lowest well tolerated blood pressure: A personalized target for all?

被引:6
作者
Verdecchia, Paolo [1 ,3 ]
Angeli, Fabio [2 ,5 ]
Reboldi, Gianpaolo [4 ]
机构
[1] Fdn Umbra Cuore & Ipertens ONLUS, Perugia, Italy
[2] Univ Insubria, Dept Med & Technol Innovat DiMIT, Varese, Italy
[3] Hosp S Maria Misericordia, Dept Cardiol, Perugia, Italy
[4] Univ Perugia, Hosp S Maria Misericordia, Dept Med & Surg, Div Nephrol, Perugia, Italy
[5] IRCCS Isti Clin Sci Maugeri, Dept Med & Cardiopulm Rehabil, Tradate, Italy
关键词
Hypertension; Guidelines; Blood pressure target; Antihypertensive treatment; Myocardial infarction; Stroke; Heart failure; INCREASED CARDIOVASCULAR RISK; CORONARY-ARTERY-DISEASE; AGED; 60; YEARS; HYPERTENSIVE PATIENTS; J-CURVE; ANTIHYPERTENSIVE TREATMENT; AMERICAN-COLLEGE; KIDNEY-DISEASE; TRIAL; ADULTS;
D O I
10.1016/j.ejim.2024.01.025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The optimal blood pressure (BP) target for prevention of cardiovascular complications of hypertension remains uncertain. Most Guidelines suggest different targets depending on age, comorbidities and treatment tolerability, but the underlying evidence is not strong. Results of randomized strategy trials comparing lower (i.e., more intensive) versus higher (i.e., less intensive) BP targets should drive the definition. However, these trials tested different BP targets based on systolic BP, diastolic BP or combined systolic and diastolic BP goals. Overall, the more intensive treatment targets reduced the risk of major cardiovascular complications of hypertension when compared with the less intensive targets, despite a higher incidence of unwanted effects including, but not limited to, hypotension, electrolyte abnormalities and renal dysfunction. Consequently, some Guidelines defined low BP thresholds (i.e., 120/70 mmHg) not to exceed downward because of the expectation that unwanted effects may outweigh the outcome benefits. The present review discusses the evidence underlying the choice of BP targets, which remains an important step in the management of hypertensive patients. We conclude that, on the ground of the heterogeneity of available data in support to fixed BP targets, their definition should be personalized in all patients and based on best trade-off between efficacy and safety, i.e., the lowest well tolerated BP.
引用
收藏
页码:42 / 48
页数:7
相关论文
共 72 条
  • [1] Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure
    Asayama, Kei
    Ohkubo, Takayoshi
    Metoki, Hirohito
    Obara, Taku
    Inoue, Ryusuke
    Kikuya, Masahiro
    Thijs, Lutgarde
    Staessen, Jan A.
    Imai, Yutaka
    [J]. HYPERTENSION RESEARCH, 2012, 35 (11) : 1102 - 1110
  • [2] Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta-Analysis of Randomized Trials
    Bangalore, Sripal
    Toklu, Bora
    Gianos, Eugenia
    Schwartzbard, Arthur
    Weintraub, Howard
    Ogedegbe, Gbenga
    Messerli, Franz H.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2017, 130 (06) : 707 - U382
  • [3] J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial†
    Bangalore, Sripal
    Messerli, Franz H.
    Wun, Chuan-Chuan
    Zuckerman, Andrea L.
    DeMicco, David
    Kostis, John B.
    LaRosa, John C.
    [J]. EUROPEAN HEART JOURNAL, 2010, 31 (23) : 2897 - 2908
  • [4] Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control
    Beddhu, Srinivasan
    Chertow, Glenn M.
    Cheung, Alfred K.
    Cushman, William C.
    Rahman, Mahboob
    Greene, Tom
    Wei, Guo
    Campbell, Ruth C.
    Conroy, Margaret
    Freedman, Barry I.
    Haley, William
    Horwitz, Edward
    Kitzman, Dalane
    Lash, James
    Papademetriou, Vasilios
    Pisoni, Roberto
    Riessen, Erik
    Rosendorff, Clive
    Watnick, Suzanne G.
    Whittle, Jeffrey
    Whelton, Paul K.
    [J]. CIRCULATION, 2018, 137 (02) : 134 - 143
  • [5] Benavente OR, 2013, LANCET, V382, P506
  • [6] Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering Findings From the SPRINT Randomized Clinical Trial
    Berry, Jarett D.
    Nambi, Vijay
    Ambrosius, Walter T.
    Chen, Haiying
    Killeen, Anthony A.
    Taylor, Addison
    Toto, Robert D.
    Soliman, Elsayed Z.
    McEvoy, John W.
    Pandey, Ambarish
    Joshi, Parag H.
    Blankenberg, Stefan
    Kitzman, Dalane W.
    Ballantyne, Christie M.
    de Lemos, James A.
    [J]. JAMA CARDIOLOGY, 2021, 6 (12) : 1397 - 1405
  • [7] Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials
    Boehm, Michael
    Schumacher, Helmut
    Teo, Koon K.
    Lonn, Eva M.
    Mahfoud, Felix
    Mann, Johannes F. E.
    Mancia, Giuseppe
    Redon, Josep
    Schmieder, Roland E.
    Sliwa, Karen
    Weber, Michael A.
    Williams, Bryan
    Yusuf, Salim
    [J]. LANCET, 2017, 389 (10085) : 2226 - 2237
  • [8] Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events
    Bress, Adam P.
    Greene, Tom
    Derington, Catherine G.
    Shen, Jincheng
    Xu, Yizhe
    Zhang, Yiyi
    Ying, Jian
    Bellows, Brandon K.
    Cushman, William C.
    Whelton, Paul K.
    Pajewski, Nicholas M.
    Reboussin, David
    Beddu, Srinivasan
    Hess, Rachel
    Herrick, Jennifer S.
    Zhang, Zugui
    Kolm, Paul
    Yeh, Robert W.
    Basu, Sanjay
    Weintraub, William S.
    Moran, Andrew E.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (16) : 1977 - 1990
  • [9] Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States Projections From NHANES (National Health and Nutrition Examination Survey)
    Bress, Adam P.
    Kramer, Holly
    Khatib, Rasha
    Beddhu, Srinivasan
    Cheung, Alfred K.
    Hess, Rachel
    Bansal, Vinod K.
    Cao, Guichan
    Yee, Jerry
    Moran, Andrew E.
    Durazo-Arvizu, Ramon
    Muntner, Paul
    Cooper, Richard S.
    [J]. CIRCULATION, 2017, 135 (17) : 1617 - +
  • [10] The Magic of Randomization versus the Myth of Real-World Evidence
    Collins, Rory
    Bowman, Louise
    Landray, Martin
    Peto, Richard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07) : 674 - 678